Tag Archives: EU

EFPIA’s “Integrated Strategy”: Out of the Frying Pan, Into the Fire?

It’s difficult to open an email or an envelope in Brussels these days without yet another agenda falling out of it, carrying the promise of a new start. With a new European Parliament installed, a new European Commission president appointed and a new Commission on the way, and guarded optimism that the worst of the […]
Posted in Europe, Global, Op-Ed, Regulatory | Also tagged , , | Leave a comment

EMA Responds Robustly to Conflict-of-Interest Claims

By Philip Ward, Applied Clinical Trials. The European Medicines Agency (EMA) has insisted that the concerns raised about its scientific advice given to pharmaceutical companies stem from a flawed understanding of the activities of the agency and its partners in this area.
Posted in Europe, Global, Guest Blog, Regulatory | Also tagged , , , , | Leave a comment

Further Boost for Europe’s Largest Healthcare Partnership

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has announced the launch of IMI2, with a budget of €3.3 billion (US$ 4.5 bn). IMI (the Innovative Medicines Initiative) is a public-private partnership (PPP) between the European Commission and EFPIA, and was already the largest healthcare PPP in Europe. The budget for its first phase (2008-2013) […]
Posted in Europe, Global | Also tagged , , , , | Leave a comment

European Pharma Policy Reaches "New Level of Timidity"

By Peter O’ Donnell, Applied Clinical Trials. The European Union has managed to snatch defeat from the jaws of opportunity once more! A long-heralded document portentously entitled “Pharmaceutical industry: a strategic sector for the European economy,” and supposedly initiating a new start in long-term thinking about boosting the drug industry, squeezes the thinnest and weakest […]
Posted in Europe, Guest Blog, Op-Ed, Regulatory | Also tagged , | Leave a comment

Eight Lessons for Enhancing Compliance Effectiveness in Europe

Andy Bender and Geert van Gansewinkel outline eight lessons for executing a soft change program for enhancing compliance effectiveness within European life sciences organizations. The European compliance and transparency landscape has changed rapidly over the last couple of years. Over and above the challenging compliance landscape, there is additional complexity impacting transparency relating to the […]
Posted in compliance, Europe, Global, Guest Blog | Also tagged , , | Leave a comment
  • Categories

  • Meta